Description: Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-11, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Home Page: www.lanternpharma.com
LTRN Technical Analysis
1920 McKinney Avenue
Dallas,
TX
75201
United States
Phone:
972 277 1136
Officers
| Name | Title |
|---|---|
| Mr. Panna Sharma PH.D. | Pres, CEO & Director |
| Mr. David R. Margrave | CFO & Sec. |
| Dr. Kishor Gopaldas Bhatia Ph.D. | Chief Scientific Officer & Scientific Consultant |
| Nicole Leber | Investor Relations Associate, Fin. & Admin. Coordinator |
| Dr. Peter L. Nara D.V.M., M.S., Ph.D. | Co-Founder & Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9933 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-06-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |